Welcome, Guest
Username: Password: Remember me
The Company
  • Page:
  • 1

TOPIC: Why no mention of OA results in this release?

Why no mention of OA results in this release? 05 Jan 2016 19:11 #5922

  • paul
  • paul's Avatar Topic Author
  • Offline
  • Senior Boarder
  • Senior Boarder
  • Posts: 55
  • Thank you received: 6
Cytori Therapeutics to Provide Corporate Update at 2016 Biotech Showcase™
Presentation on January 12, 2016 at 4:30 PM Pacific Time

January 05, 2016 05:10 PM Eastern Standard Time
SAN DIEGO--(BUSINESS WIRE)--Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that the company will present at the Biotech Showcase™ at 4:30 PM Pacific Time (7:30 PM Eastern Time) on Tuesday, January 12, 2016. The presentation will take place in the B-Mission I room at the Parc 55 Wyndham Hotel in San Francisco.

Dr. Marc Hedrick, CEO and President of Cytori Therapeutics, will provide an update on current corporate activities and recent developments, including progress on the STAR trial, the U.S. phase III trial focused on Scleroderma related hand dysfunction.

A live audio webcast of the presentation will be available under the investor relations section of Cytori’s website at www.cytori.com . A replay of the presentation will be available for 90 days following the event. Please connect to Cytori’s website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Biotech Showcase

The Biotech Showcase 2016 Conference ( www.ebdgroup.com/bts/index.php ) is one of the most significant healthcare investor conferences of the year. It is designed to provide private and public biotechnology and life sciences companies the opportunity to present to, and meet with, public and private investors, and pharmaceutical executives. This is the 8th year for the Biotech Showcase. More than 2100 investors and biopharmaceutical executives from around the world are expected to attend.

About Cytori

Cytori Therapeutics is a late stage cell therapy company developing autologous cell therapies from adipose tissue to treat a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products. For more information: visit www.cytori.com .

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking statements that involve known and unknown risks and uncertainties. All statements, other than historical facts are forward looking statements. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. These risks and uncertainties are described under the "Risk Factors" in Cytori's Securities and Exchange Commission Filings, included in our annual and quarterly reports.

There may be events in the future that we are unable to predict, or over which we have no control, and our business, financial condition, results of operations and prospects may change in the future. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless we have an obligation under U.S. Federal securities laws to do so.

Please Log in or Create an account to join the conversation.

Why no mention of OA results in this release? 05 Jan 2016 19:57 #5923

  • franshei
  • franshei's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 790
  • Thank you received: 103
Paul, I think Hedrick will present a global view on all the ongoing clinical r/d programs (including the OA study) and commercial activities with emphasis on scleroderma (the initiation was highlighted in the 2015 Showcase). In December, 2015, CYTX reports the EU 12 month scleroderma data and yet the PR has not generated much impact on the PPS. According to DOV, that PR is a very significant finding. Now with the warrant issue being resolved somehow, I think Hedrick or Kesten will present more detail information next week. The target audience will be the big boys.

I think the OA interim data will be released separately (as discussed in the November CC).
The following user(s) said Thank You: paul

Please Log in or Create an account to join the conversation.

  • Page:
  • 1
Time to create page: 0.083 seconds

Copyright Information

Copyright Fas Kuiters © 2016 young-foxes.com. All Rights Reserved.
This page is made with Joomla CMS and its various templates designed by Fas Kuiters with the excellent Themler tool.



Shared Spreadsheet Links

DOV´s Revised Projections for the Periods 2017 until 2020

Shareble link : HERE

Fas Kuiters Websites